| Field | Specification |
|---|---|
| Target | |
| Alternative names | 225Ac-lintuzumab, HuM195, SGN-33, SMART M195, HuM195 |
| UniProt # | |
| CAS no. | |
| Reactivity | |
| Applications | |
| Assay type | |
| Sample type(s) | Plasma, Serum |
| Sensitivity | |
| Detection range | |
| Detection method | |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Assay Principle
Lintuzumab ELISA Kit provides plate-based quantitative measurement of Lintuzumab. Each run carries its own standard series, so results remain comparable across plates, days, and operators in a research workflow.
Background
Lintuzumab is a humanized monoclonal antibody, HuM195, that targets the cell surface antigen CD33 that is expressed on the vast majority of acute myeloid leukemia (AML) cells. [225Ac]Ac-lintuzumab clinical trials were discussed in detail in reference. An initial phase I dose-escalation trial demonstrated that for a single infusion of [225Ac]Ac-lintuzumab in patients with relapsed or refractory acute myeloid leukemia, the maximum tolerated dose (MTD) was determined to be 111 kBq/kg with antileukemic activity across all dose levels. No evidence of radiation-induced nephrotoxicity was seen. Peripheral blasts were eliminated in 63% of the patients at doses of >37 kBq/kg. Bone marrow blast reduction was observed in 67% of patients. Subsequently, a multicenter phase I dose-escalation trial was conducted to define MTD, toxicity, and response rate of fractionated-dose [225Ac]Ac-lintuzumab when combined with low-dose cytarabine (LDAC) in older patients with untreated AML who were not candidates for intensive chemotherapy.
Specifications
| Assay Type | Quantitative Colorimetric ELISA |
|---|---|
| Detection Method | Colorimetric |
| Plate Format | 96-well (96T) |
| Sample Types | Plasma, Serum |
| Sensitivity | 0.156 μg/mL |
| Detection Range | 0.31-5 μg/mL |
| Recovery | 80-120% |
| Stability & Storage | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
| Shipping | 2-8 °C |
| CAS Number | 166089-32-3 |
| UniProt | P20138 |
| Alternative Names | 225Ac-lintuzumab, HuM195, SGN-33, SMART M195, HuM195 |
Performance Data
The kit provides a quantitative range of 0.31-5 μg/mL, an analytical sensitivity of 0.156 μg/mL, typical spike recovery of 80-120%. Plan sample dilutions so readouts fall within the linear portion of the standard curve, and evaluate matrix effects with dilution-linearity and spike-recovery controls.
Target Notes
The target is also referenced in the literature as 225Ac-lintuzumab, HuM195, SGN-33. Curated target information is available under UniProt accession P20138. The corresponding compound is registered under CAS 166089-32-3.
Common Research Applications
- Pharmacokinetic profiling of the drug in preclinical and translational research models
- Bioanalytical method development, bridging, and comparability studies
- Stability and formulation studies requiring reproducible concentration readouts
Safety & Handling
For Research Use Only. Not for diagnostic or therapeutic use. Handle all reagents and samples according to your institution's laboratory safety guidelines, and store components as recommended to preserve assay performance.
Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.